Want to see MLTX full AI Analyst Report?
Top Page
MoonLake Immunotherapeutics
(NASDAQ:MLTX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$10.50
▼(-32.52% Downside)
Action:Reiterated
Date:09/30/26
The score is held down primarily by the company’s pre-revenue financial profile with expanding losses and substantial ongoing cash burn, alongside bearish technical signals. Offsetting these risks are meaningful positive corporate catalysts (BLA submission and positive Phase 3 results), while valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Regulatory Progress
The BLA submission is a material step toward potential commercialization of sonelokimab in a serious inflammatory skin disease. It advances the lead asset into regulatory review, creates a defined path toward a potential U.S. launch, and could broaden MoonLake’s future revenue opportunity if approved.
Negative Factors
Pre-Revenue Business Model
MoonLake has no product revenue to offset research and operating costs, leaving its financial model dependent on capital markets financing while clinical programs advance. Until an approval and commercial launch occur, future earnings power remains tied to development execution and continued access to funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress
The BLA submission is a material step toward potential commercialization of sonelokimab in a serious inflammatory skin disease. It advances the lead asset into regulatory review, creates a defined path toward a potential U.S. launch, and could broaden MoonLake’s future revenue opportunity if approved.
Read all positive factors
MoonLake Immunotherapeutics (MLTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$908.94M
Dividend YieldN/A
Average Volume (3M)1.76M
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue GrowthN/A
EPS Growth-37.48%
CountryUS
Employees130
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.85
Shares Outstanding85,106,680
10 Day Avg. Volume1,988,658
30 Day Avg. Volume1,760,612
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-4.33
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-628.84
Enterprise Value/Ebitda-4.00
Forecast
1Y Price Target
$33.00Price Target Upside112.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.37
Revenue Forecast (FY)N/A
MoonLake Immunotherapeutics Business Overview & Revenue Model
Company Description
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigatio...
How the Company Makes Money
As a clinical-stage biotechnology company, MoonLake Immunotherapeutics does not have publicly disclosed, product-based commercial revenue and primarily funds operations through capital markets financing. The company’s cash inflows have historicall...
MoonLake Immunotherapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.60M | -2.62M | 0.00 | 0.00 | 0.00 | -4.97K |
| EBITDA | -250.82M | -219.85M | -119.58M | -43.61M | -64.30M | -53.63M |
| Net Income | -263.67M | -227.32M | -118.94M | -36.01M | -49.97M | -53.64M |
Balance Sheet | ||||||
| Total Assets | 573.95M | 424.43M | 477.93M | 526.54M | 76.84M | 9.68M |
| Cash, Cash Equivalents and Short-Term Investments | 537.03M | 393.97M | 448.03M | 511.01M | 72.11M | 8.04M |
| Total Debt | 101.53M | 75.71M | 2.83M | 3.70M | 282.58K | 15.00M |
| Total Liabilities | 145.75M | 119.95M | 24.54M | 13.05M | 8.08M | 21.33M |
| Stockholders Equity | 428.19M | 304.48M | 446.82M | 495.68M | 48.90M | -11.65M |
Cash Flow | ||||||
| Free Cash Flow | -225.18M | -196.04M | -117.11M | -43.06M | -55.91M | -35.23M |
| Operating Cash Flow | -225.18M | -196.01M | -116.59M | -42.78M | -55.89M | -35.18M |
| Investing Cash Flow | 58.91M | 202.99M | -205.60M | -25.18M | -32.34M | -50.71K |
| Financing Cash Flow | 338.14M | 146.00M | 51.31M | 479.70M | 119.69M | 43.26M |
MoonLake Immunotherapeutics Technical Analysis
Negative
15.56
Price Trends
14.04
Negative
16.56
Negative
16.66
Negative
Market Momentum
-1.00
Negative
25.24
Positive
32.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLTX, the sentiment is Negative. The current price of 15.56 is above the 20-day moving average (MA) of 11.67, above the 50-day MA of 14.04, and below the 200-day MA of 16.66, indicating a bearish trend. The MACD of -1.00 indicates Negative momentum. The RSI at 25.24 is Positive, neither overbought nor oversold. The STOCH value of 32.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLTX.
MoonLake Immunotherapeutics Risk Analysis
MoonLake Immunotherapeutics disclosed 65 risk factors in its most recent earnings report. MoonLake Immunotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MoonLake Immunotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $908.94M | -2.70 | -82.68% | ― | ― | -37.48% | |
46 Neutral | $383.32M | -3.74 | -54.98% | ― | ― | -65.84% | |
46 Neutral | $219.57M | -2.08 | -62.63% | ― | ― | ― | |
45 Neutral | $529.92M | -5.98 | -61.65% | ― | -51.05% | 57.25% | |
44 Neutral | $234.32M | -2.83 | -58.00% | ― | ― | ― | |
44 Neutral | $942.48M | -1.73 | -102.97% | ― | -63.11% | 15.36% |
* Healthcare Sector Average
MLTX
MoonLake Immunotherapeutics
10.14
0.25
2.53%
ACRS
Aclaris Therapeutics
3.38
1.45
75.13%
IFRX
InflaRx
1.48
0.23
18.40%
ZURA
Zura Bio
4.41
0.70
18.87%
ALMS
Alumis Inc.
6.06
1.21
24.95%
EVMN
Evommune, Inc.
5.77
-14.46
-71.48%
MoonLake Immunotherapeutics Corporate Events
Product-Related AnnouncementsRegulatory Filings and Compliance
MoonLake files FDA application for sonelokimab therapy
Positive
Sep 30, 2026
On September 30, 2026, MoonLake Immunotherapeutics submitted a Biologics License Application to the U.S. Food and Drug Administration for sonelokimab, its tri-specific nanobody, as a treatment for moderate-to-severe hidradenitis suppurativa in adu...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
MoonLake announces positive Phase 3 psoriatic arthritis results
Positive
Aug 10, 2026
On August 10, 2026, MoonLake reported positive topline week 16 results from its Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve adults with active psoriatic arthritis, with the 60 mg induction regimen meeting all clinical endpoints. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.